News | August 06, 2025
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Subscribe To Our Newsletter & Stay Updated
